A Label Almost Everyone Knows
Few families today do not know a child “diagnosed with hyperactivity” who takes a pill every day. From a distance, it looks like good news: a problem is identified and treated. But before accepting that narrative at face value, it pays to pause, because the diagnostic category underpinning the entire process is far more fragile than its widespread acceptance suggests.
A Syndrome Is Not a Disease
ADHD—Attention Deficit Hyperactivity Disorder—is classified as a syndrome, not a disease in the strict medical sense. A disease has a verifiable biological basis: an infection, an identifiable lesion, or measurable tissue degeneration. In ADHD, no underlying organic pathology has ever been identified. What exists instead is a cluster of behaviors that frequently appear together—difficulty maintaining attention, easy distractibility, impulsivity, emotional instability, defiance, adaptation difficulties—and which, because they co-occur, receive a common clinical label. Sharing a label, however, does not mean sharing a single cause.
Can Genetics Explain It?
Advocates who defend ADHD as a biological disease have spent decades searching for its physiological substrate without conclusive success. An estimated prevalence of around 8% is frequently cited, alongside claims that the origin is “highly genetic,” located in dopamine and norepinephrine dysfunction within the frontal cortex responsible for executive functions. The trouble is that these explanations remain working hypotheses. The DSM itself—psychiatry’s benchmark diagnostic manual—concedes that no laboratory tests or neurological assessments exist to confirm the disorder.
In the absence of objective measurements, diagnosis relies on interpreting the child’s behavior, bringing with it immense subjectivity: what one adult views as “pathological restlessness,” another sees as temperament, boredom, or a poor fit with a rigid environment. While some children may well have a genetic predisposition—such as a naturally more active temperament—a predisposition is not a cause: it always interacts with context, parenting, and learned behavior.
If the Cause Is Environmental, Why Prescribe a Drug?
This highlights the fundamental contradiction. If a large part of the problem stems from environmental factors, the response ought to focus primarily on the environment as well. Methylphenidate, the medication most commonly prescribed, is a stimulant related to amphetamines that increases dopamine and norepinephrine levels throughout the nervous system. Its most prized effect in children labeled with ADHD—helping them stay focused on a task—is hardly a novel discovery: stimulants have historically been used for that exact purpose, as college students studying for finals know all too well. The fact that a drug “works” by temporarily boosting concentration does not prove it is correcting an underlying disease; healthy individuals without any diagnosis experience the very same boost.
From Restlessness to Profit: Disease Mongering
Despite this, many clinicians continue to claim ADHD is underdiagnosed, a message widely amplified across mainstream media. One plausible explanation for this relentless push is economic: methylphenidate sales have skyrocketed over recent decades. This enters the realm of disease mongering: widening the boundaries of pathology until normal behavioral variations are transformed into clinical diagnoses that open lucrative markets.
German science journalist Jörg Blech explored this dynamic in Inventing Disease, arguing that the concept of the “hyperactive child” has been aggressively cultivated, with pharmaceutical companies and key opinion leaders working for years to frame restless or unfocused kids as patients in need of medication. In the Spanish-speaking world, authors such as Miguel Jara (Health Traffickers) and physician Antonio Palomar, writing in the newspaper Diagonal, have documented similar mechanisms driving the medicalization of everyday life. This ecosystem is not confined to doctors and drug manufacturers: in some countries, schools are also incentivized. In the United States, for instance, public schools have reportedly received targeted subsidies for each student classified with special needs or behavioral disorders—a financial incentive that, if present, inevitably warps objective clinical standards.
A Critical Perspective
This debate calls for nuance rather than reactionary dismissal. Denying that ADHD is a distinct biological disease is not the same as denying that children—and adults—experience genuine suffering, with real challenges in focus, impulsivity, or emotional regulation that complicate school and home life. The issue is not recognizing that distress, but the knee-jerk progression from disruptive behavior to a lifelong diagnostic label, and from that label straight to a pill, skipping vital questions along the way: what role is played by environment, classroom dynamics, sleep, parenting, or unrealistic adult expectations?
Three sensible precautions are worth keeping in mind. First, approach round statistics and claims of settled science with skepticism when the scientific literature remains divided. Second, pay attention to conflicts of interest: who funds the research, public awareness campaigns, and clinical guidelines is never an irrelevant detail. Third, remember that methylphenidate is a central nervous system stimulant with systemic effects that demands rigorous medical oversight, not an innocuous supplement. This article is for educational purposes and is not a substitute for advice from a healthcare professional; any treatment decisions belong to the family in consultation with their healthcare team, ideally through a lens that looks well beyond the prescription pad.
